Abstract
Soluble amyloid β (Aβ) oligomers might trigger early cognitive deficit in Alzheimers Disease (AD) through the impairment of proper neuronal network function. We have recently shown that the short sequence Aβ25-35 affects the spontaneous activity in hippocampal slices, when was added to the bath, at high nanomolar concentrations. In the present study, we aimed to characterize the effects of the oligomerized full length sequence Aβ1-42 on the spontaneous network activity in the CA1 hippocampal area testing whether such effects are age dependent. By performing extracellular field recordings of spontaneous network activity of hippocampal slices, we found that an oligomerized solution of Aβ1-42 (osAβ) potently inhibit, in a dose-dependent manner, the spontaneous hippocampal network activity with an IC50 of 0.4 ± 3.2 nM and a maximal effect reached around 10 nM. While spontaneous hippocampal network activity is unaffected by age, the sensitivity of spontaneous hippocampal network activity to osAβ (10 nM) appears to be increased in slices from older animals. Moreover, to see a significant reduction in spontaneous network activity in slices from animals in their second week of life 100nM osAβ was needed. The osAβ-induced reduction in hippocampal network activity is accompanied by a presynaptic reduction in both spontaneous and miniature synaptic potentials. Finally, we demonstrated that the effect produced by osAβ on spontaneous network activity was specific, reversible and unrelated with cell death. In conclusion, our data show that osAβ alters hippocampal network activity at concentrations commonly observed in AD patients and that such effect of osAβ increases with age.
Keywords: Alzheimer's disease, amyloid β oligomers, hippocampal spontaneous activity, age
Current Alzheimer Research
Title: Amyloid β Oligomers Decrease Hippocampal Spontaneous Network Activity in an Age-Dependent Manner
Volume: 7 Issue: 5
Author(s): H. Balleza-Tapia, A. Huanosta-Gutierrez, A. Marquez-Ramos, N. Arias and F. Pena
Affiliation:
Keywords: Alzheimer's disease, amyloid β oligomers, hippocampal spontaneous activity, age
Abstract: Soluble amyloid β (Aβ) oligomers might trigger early cognitive deficit in Alzheimers Disease (AD) through the impairment of proper neuronal network function. We have recently shown that the short sequence Aβ25-35 affects the spontaneous activity in hippocampal slices, when was added to the bath, at high nanomolar concentrations. In the present study, we aimed to characterize the effects of the oligomerized full length sequence Aβ1-42 on the spontaneous network activity in the CA1 hippocampal area testing whether such effects are age dependent. By performing extracellular field recordings of spontaneous network activity of hippocampal slices, we found that an oligomerized solution of Aβ1-42 (osAβ) potently inhibit, in a dose-dependent manner, the spontaneous hippocampal network activity with an IC50 of 0.4 ± 3.2 nM and a maximal effect reached around 10 nM. While spontaneous hippocampal network activity is unaffected by age, the sensitivity of spontaneous hippocampal network activity to osAβ (10 nM) appears to be increased in slices from older animals. Moreover, to see a significant reduction in spontaneous network activity in slices from animals in their second week of life 100nM osAβ was needed. The osAβ-induced reduction in hippocampal network activity is accompanied by a presynaptic reduction in both spontaneous and miniature synaptic potentials. Finally, we demonstrated that the effect produced by osAβ on spontaneous network activity was specific, reversible and unrelated with cell death. In conclusion, our data show that osAβ alters hippocampal network activity at concentrations commonly observed in AD patients and that such effect of osAβ increases with age.
Export Options
About this article
Cite this article as:
Balleza-Tapia H., Huanosta-Gutierrez A., Marquez-Ramos A., Arias N. and Pena F., Amyloid β Oligomers Decrease Hippocampal Spontaneous Network Activity in an Age-Dependent Manner, Current Alzheimer Research 2010; 7 (5) . https://dx.doi.org/10.2174/156720510791383859
DOI https://dx.doi.org/10.2174/156720510791383859 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiepileptogenic Effect of Retinoic Acid
Current Neuropharmacology Valproic Acid Metabolism and its Consequences on Sexual Functions
Current Drug Metabolism Experimental Models for the Discovery of Novel Anticonvulsant Drugs: Focus on Pentylenetetrazole-Induced Seizures and Associated Memory Deficits
Current Pharmaceutical Design Neuronal Nicotinic Receptors as Brain Targets for Pharmacotherapy of Drug Addiction
CNS & Neurological Disorders - Drug Targets MicroRNA-451 Aggravates Kainic Acid-induced Seizure and Neuronal Apoptosis by Targeting GDNF
Current Neurovascular Research Blood-brain Barrier Drug Discovery for Central Nervous System Infections
Current Drug Targets - Infectious Disorders The Quest for Eldorado: Development of Radioligands for In Vivo Imaging of Nicotinic Acetylcholine Receptors in Human Brain
Current Pharmaceutical Design Liver-Brain Axis in Sporadic Alzheimer’s Disease: Role of Ten Signature Genes in a Mouse Model
CNS & Neurological Disorders - Drug Targets Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Rethinking the Excitotoxic Ionic Milieu:The Emerging Role of Zn 2+ in Ischemic Neuronal Injury
Current Molecular Medicine NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease
Current Neuropharmacology Histamine H3 Receptor: A Potential Drug Target for the Treatment of Central Nervous System Disorders
Current Drug Targets - CNS & Neurological Disorders Nicotinic Acetylcholine Receptors and Epilepsy
Current Drug Targets - CNS & Neurological Disorders Overview of Chemistry and Therapeutic Potential of Non-Nitrogen Heterocyclics as Anticonvulsant Agents
Current Neuropharmacology Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Chromosomal Micro-aberration in a Saudi Family with Juvenile Myoclonic Epilepsy
CNS & Neurological Disorders - Drug Targets Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer’s Disease
Current Protein & Peptide Science Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Recent Advancements in Nanodiamond Mediated Brain Targeted Drug Delivery and Bioimaging of Brain Ailments: A Holistic Review
Pharmaceutical Nanotechnology Peptides Targeting Gap Junctional Structures
Current Pharmaceutical Design